For research use only. Not medical advice.
Overview
Mazdutide (LY3437943) is a dual GLP-1/glucagon agonist similar to survodutide but generally smoother and more tolerable, with a softer glucagon hit and less aggressive appetite suppression.
Typical weekly exploration ranges from 2–10 mg, with gradual escalation over 8–12 weeks.
It has good synergy with GLP-1/GIP agonists (e.g., tirzepatide) and is commonly used in “Ghetto Reta” stacks due to its cleaner side-effect profile.
Weekly Titration Schedule
Weeks 1–2: Intro Phase
Dose: 2 mg once weekly
Purpose: Establish baseline tolerability and assess GI sensitivity.
Notes: This is a gentle entry point compared to survodutide’s 0.6 mg start.
Weeks 3–4: Light Phase
Dose: 4 mg once weekly
Produces noticeable appetite reduction but usually without overwhelming gastric slowing.
Hold at 2 mg longer if nausea persists.
Weeks 5–6: Moderate Phase
Dose: 6 mg once weekly
This is the working dose for many research subjects.
Represents a good balance of efficacy and tolerability.
Weeks 7–8: Strong Phase
Dose: 8 mg once weekly
Strong metabolic effects emerge here.
Suitable for subjects who tolerated 6 mg without significant GI burden.
Weeks 9–12: Upper-Tier Phase
Dose: 10 mg once weekly
This is the practical “top end” for most research setups.
Only escalate to 10 mg after several weeks of stability at 8 mg.
Maintenance Dosing (Week 13+)
Standard Maintenance
6–8 mg once weekly
Best balance for long-term tolerability.
High-End Maintenance
10 mg once weekly
Used when the goal is more aggressive metabolic impact or retatrutide-like synergy in stacks.
Frequency & Timing
Once weekly, same day each week.
Delayed GI effects can occur (Day 2–3), especially at ≥6 mg.
When stacking with tirzepatide, escalations should be slower than this standalone schedule.
Cycle Length
Titration requires 8–12 weeks depending on sensitivity.
Full research cycles often run 16–48 weeks, typically maintaining 6–10 mg.
Common Research Notes
Mazdutide is smoother and less nausea-inducing compared to survodutide.
Appetite suppression is strong but less abrupt subjects often describe it as “cleaner” or “more natural.”
When stacked with tirzepatide, GI effects compound; many researchers cap mazdutide at 4–6 mg in combination protocols.
